Russia’s new Covid-19 vaccine has passed early trial test and the patients involved in early tests developed antibodies with no serious adverse effects
A research article published in The Lancet reported that two small trials, each involving 38 healthy adults aged between 18 and 60, were given a two-part immunisation.
As per the report, the participants were monitored over 42 days and all developed antibodies within the first three weeks.
Also, over 76 participants of these trials would be monitored up to 180 days and more rigorous phase 3 clinical trial was planned with the involvement of 40,000 volunteers from different age and risk groups.
The data showed that the vaccine was "safe, well tolerated, and does not cause serious adverse events in healthy adult volunteers".
